Home > Boards > US Listed > Medical - Healthcare > Second Sight Medical Products Inc (EYES)

LOS ANGELES--(BUSINESS WIRE)--Sep. 22, 2020-- Second Sight Medical

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Big Barnie Member Profile
 
Followed By 2
Posts 893
Boards Moderated 1
Alias Born 07/11/13
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/10/2021 1:09:20 PM
UiPath, Campbell among premarket losers' pack Seeking Alpha - 6/9/2021 8:25:44 AM
Second Sight Medical files for $250 million mixed securities shelf offering Seeking Alpha - 6/9/2021 6:55:08 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 6/8/2021 5:01:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2021 6:04:01 AM
Second Sight Medical Products Announces Results of its 2021 Annual Meeting Business Wire - 6/1/2021 6:00:00 AM
Second Sight Medical trades higher on news of patent win Seeking Alpha - 5/21/2021 12:16:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2021 6:03:48 AM
Second Sight Medical Products Announces Year Three NIH Funding of Its Orion Study Business Wire - 5/13/2021 6:00:00 AM
Second Sight Medical reports two-year results of its Orion study Seeking Alpha - 5/12/2021 6:25:26 AM
Second Sight Medical Products Announces Two-Year Results of its Orion Study Business Wire - 5/12/2021 6:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/30/2021 5:25:08 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/29/2021 6:16:20 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/27/2021 5:40:31 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/27/2021 4:10:30 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/22/2021 4:42:52 PM
Second Sight slips 8% on launch of stock offering Seeking Alpha - 4/16/2021 8:34:12 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 4/16/2021 6:02:07 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 4/7/2021 6:02:22 AM
Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors Business Wire - 4/6/2021 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2021 6:29:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/5/2021 9:19:25 AM
Second Sight Medical terminates business combination with Pixium Vision Seeking Alpha - 4/3/2021 9:13:41 PM
Second Sight Medical appoints new acting CEO Seeking Alpha - 4/1/2021 1:29:12 PM
Second Sight Medical Products Names Scott Dunbar Acting CEO Business Wire - 4/1/2021 8:00:00 AM
Big Barnie   Tuesday, 09/22/20 01:08:12 PM
Re: None
Post # of 1174 

LOS ANGELES--(BUSINESS WIRE)--Sep. 22, 2020-- Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) at UCLA Medical Center (“UCLA”). The study, which includes four participants at UCLA and two participants at Baylor College of Medicine (“Baylor”), was paused for in-person visits following the guidelines for clinical trials at each institution in March 2020 due to COVID-19. Study visits have now been resumed; several UCLA participants are being examined this week, and Baylor is anticipated to resume its study soon.

The first human subject was implanted with Orion in January 2018. A total of six subjects have been implanted in the Orion Early Feasibility Study.

“We are delighted that the Early Feasibility Study has restarted. The study, like many such investigations, was suspended as medical centers focused attention and resources on their COVID-19 response and to protect the health of study participants. Our highest priority remains the health and safety of all of our study participants, and we look forward to continuing this important research. We remain committed to this innovative technology and believe that Orion has the potential to safely benefit blind individuals and help them to perform everyday tasks,” stated Matt Pfeffer, Acting Chief Executive Officer.

Orion is a breakthrough technology intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion converts images captured by a miniature video camera mounted on glasses into a series of small electrical pulses transmitted wirelessly to electrodes implanted directly on the visual cortex of the individual subject’s brain.

In June 2019, the study’s principal investigators, Nader Pouratian, MD, Ph.D. of UCLA and Daniel Yoshor, MD of Baylor, presented 12-month results from the Early Feasibility Study at the World Society for Stereotactic and Functional Neurosurgery Annual Meeting in New York City. On both the primary and secondary outcome measures, latest results at 12 months have been positive.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences